PHOTOTHERAPY OF INTRACAVITARY SPACES

腔内空间的光疗

• 批准号: 3916586
• 负责人: A RUSSO
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3916586
• 关键词: athymic mouse; combination cancer therapy; disease /disorder model; dogs; drug administration routes; drug adverse effect; drug delivery systems; drug metabolism; drug screening /evaluation; heme; laboratory mouse; laser therapy; malignant ascites; neoplasm /cancer immunotherapy; neoplasm /cancer photoradiation therapy; nonvisual photosensitivity; ovary neoplasms; pharmacokinetics; porphyrins; radiation therapy dosage; tissue /cell culture

The use of hematoporphyrin derivative and other photosensitizing agents in combination with light activation is currently being investigated as an anti-tumor modality for the treatment of intraperitoneal and intrathoracic tumors. A major advantage of this modality is the apparent selective retention of the sensitizing dye within tumors. A murine ascites ovarian carcinoma and a human ovarian tumor that grows as an ascites tumor has been used to study the characteristics of drug distribution in the peritoneal cavity. Likewise, murine models have been used to study the tolerance of the thoracic cavity structures to the phototherapy techniques being explored. The limitations of the murine model has required the extensions of the investigation to the canine model for evaluation of the toxicity of Phototherapy. Different wavelengths of light, different laser delivery systems, different sensitizers, different doses of energy, different modes of drug administration, and different monitoring devices are being studied. We have shown that Phototherapy can be used to effectively treat a murine ascites tumor. We have also shown that in both the murine and the canine model, the peritoneal serosal surface is tolerant of at least 0.5 J/cm2 and that this work can be extended to human subjects. In the murine system, we have shown that the thoracic cavity, like the peritoneal cavity, is exquisitely sensitive to treatment with red light (630 nm). The dose rate must be controlled to minimize heat build up (less than 150 mW fiber output from a forward projecting optical fiber is usually tolerated). We are exploring the use of photoimmunotherapy as an additional means of drug delivery. We are exploring the use of chemiluminescence as a means of light delivery to the cavitary spaces.

血卟啉衍生物等光敏剂的使用 与光激活相结合的试剂目前正在 作为一种抗肿瘤方法被研究用于治疗 腹膜和胸腔内肿瘤。的一个主要优势 这种形式是明显的选择性保留 使肿瘤内的染料敏化。小鼠腹水型卵巢癌 一种以腹水肿瘤的形式生长的人卵巢肿瘤已经 用来研究药物在体内的分布特征 腹膜腔。同样，小鼠模型也被用来研究 胸腔结构对光疗的耐受性 正在探索的技术。小鼠模型的局限性是 要求将调查范围扩大到犬类模型 用于评估光疗的毒性。不同 光的波长，不同的激光传输系统，不同的 致敏剂，不同剂量的能量，不同模式的药物 目前正在研究不同的监测设备。 我们已经证明，光疗可以有效地治疗 小鼠的腹水瘤。我们还表明，在这两只小鼠身上 与犬模型相比，腹膜浆膜表面耐受 至少0.5J/cm2，这项工作可以推广到人类 研究对象。在小鼠的系统中，我们已经证明了胸椎 腔，就像腹膜腔一样，对 红光(630 Nm)处理。剂量率必须是 控制以最大限度地减少热量积累(低于150 mW的光纤输出 从前向投射的光纤发出的信号通常是允许的)。我们 正在探索使用光免疫疗法作为另一种手段 药物递送。我们正在探索化学发光的用途 作为一种光传输到空腔空间的方式。